switching between glp-1 agonists ada GLP‐1 receptor in clinical practice: Expert consensus and practical guidance - Jain - 2021 - International Journal of Clinical Practice Summary of the effects on

[15] [16] Gastrointestinal symptoms may be misattributed to fatigue or may coexist with and contribute to tiredness

Future studies will be crucial in addressing existing challenges, optimizing dosing regimens, and expanding their applications to maximize their impact on patient care

Gasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBN, Sparre-Ulrich AH, Veedfald S, Stensen S, Lanng AR, Bergmann NC, Christensen MB, Vilsbll T, Holst JJ, Rosenkilde MM, Knop FK

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial

GLP-1 prescriptions compared to Novos 42%

Given the benefits of rapid diffusion, favorable blood-brain barrier permeability and versatile administration routes, these small molecule compounds will be one of the important candidates of GLP-1RA